Following these studies TNF-α-inhibitory drugs such as the monoclonal antibodies infliximab and adalimumab and the competitive soluble TNF-α receptor etanercept are now in use in the clinic for the treatment of steroid-refractory GvHD (30). Here, TNF is linked to graft versus host disease.